Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment.
Colorectal cancer
Poly adenosine diphosphate-ribose
Poly adenosine diphosphate-ribose polymerase-1
Poly-adenosine diphosphate ribosylation
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Jun 2021
15 Jun 2021
Historique:
received:
25
02
2021
revised:
22
04
2021
accepted:
08
05
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
The development of colorectal cancer (CRC) can result from changes in a variety of cellular systems within the tumor microenvironment. Particularly, it is primarily associated with genomic instability that is the gradual accumulation of genetic and epigenetic changes consisting of a characteristic set of mutations crucial for pathways in CRC progression. Based on this background, the potential to focus on poly [adenosine diphosphate (ADP)-ribose] polymerase (PARP)-1 and poly-ADP ribosylation (PARylation) as the main causes of malignant formation of CRC may be considered. One of the important functions of PARP-1 and PARylation is its deoxyribonucleic acid (DNA) repair function, which plays a pivotal role in the DNA damage response and prevention of DNA damage maintaining the redox homeostasis involved in the regulation of oxidation and superoxide. PARP-1 and PARylation can also alter epigenetic markers and chromatin structure involved in transcriptional regulation for the oncogenes or tumor suppressor genes by remodeling histone and chromatin enzymes. Given the high importance of these processes in CRC, it can be considered that PARP-1 and PARylation are at the forefront of the pathological changes required for CRC progression. Therefore, this review addresses the current molecular biological features for understanding the multifactorial function of PARP-1 and PARylation in CRC related to the aforementioned roles; furthermore, it presents a summary of recent approaches with PARP-1 inhibition in non-clinical and clinical studies targeting CRC. This understanding could help embrace the importance of targeting PARP-1 and PARylation in the treatment of CRC, which may present the potential to identify various research topics that can be challenged both non-clinically and clinically.
Identifiants
pubmed: 34163574
doi: 10.4251/wjgo.v13.i6.574
pmc: PMC8204356
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
574-588Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: We have no conflict of interest to declare.
Références
Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24
pubmed: 22713970
Mol Cancer Res. 2014 Aug;12(8):1069-80
pubmed: 24916104
J Cell Physiol. 2018 Jul;233(7):5119-5132
pubmed: 29215746
Invest New Drugs. 2019 Oct;37(5):948-960
pubmed: 30612311
J Exp Clin Cancer Res. 2018 Mar 13;37(1):57
pubmed: 29534749
Cancer Lett. 2019 Apr 10;447:86-92
pubmed: 30677446
J Cell Physiol. 2016 Jan;231(1):3-14
pubmed: 26040249
Cancers (Basel). 2020 Feb 25;12(3):
pubmed: 32106627
Cancer Biol Med. 2019 Aug;16(3):396-414
pubmed: 31565474
Oncotarget. 2017 May 16;8(20):33972-33989
pubmed: 28430641
Curr Opin Struct Biol. 2018 Dec;53:187-198
pubmed: 30481609
Clin Cancer Res. 2008 Oct 1;14(19):5939-40
pubmed: 18829469
World J Gastroenterol. 2004 Nov 1;10(21):3218-20
pubmed: 15457580
Oncotarget. 2017 Jul 20;8(51):89142-89148
pubmed: 29179506
Trends Biochem Sci. 2017 Mar;42(3):206-218
pubmed: 27816326
J Natl Cancer Inst. 2004 Jan 7;96(1):56-67
pubmed: 14709739
Med Sci (Basel). 2018 Apr 13;6(2):
pubmed: 29652830
Oncogene. 2018 Feb 15;37(7):839-846
pubmed: 29059163
Eurasian J Med. 2018 Oct;50(3):193-201
pubmed: 30515042
Cell Discov. 2016 Feb 16;2:15046
pubmed: 27462443
Patholog Res Int. 2011 Mar 15;2011:219309
pubmed: 21437184
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12752-7
pubmed: 25136112
ISRN Oncol. 2012;2012:139268
pubmed: 23209942
Genetika. 2006 Sep;42(9):1170-85
pubmed: 17100086
Mol Cell Biol. 2010 Jan;30(1):22-32
pubmed: 19841063
Front Mol Biosci. 2019 Aug 07;6:65
pubmed: 31440515
Exp Cell Res. 2014 Nov 15;329(1):85-93
pubmed: 25281304
Gut. 2002 Jul;51(1):56-9
pubmed: 12077092
Gastroenterology. 2010 Jun;138(6):2059-72
pubmed: 20420946
Front Oncol. 2013 Nov 12;3:277
pubmed: 24282781
J Biol Chem. 2011 Mar 25;286(12):10690-701
pubmed: 21233213
Cell. 2017 Feb 9;168(4):644-656
pubmed: 28187286
Nucleic Acids Res. 2019 Dec 2;47(21):11250-11267
pubmed: 31566235
Free Radic Biol Med. 2014 Feb;67:69-80
pubmed: 24140708
Cancer Metastasis Rev. 2018 Mar;37(1):159-172
pubmed: 29318445
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824490
Cell Biosci. 2019 Dec 2;9:97
pubmed: 31827763
Neoplasia. 2018 Sep;20(9):943-950
pubmed: 30121009
Drug Des Devel Ther. 2018 Mar 21;12:605-617
pubmed: 29606854
Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12):
pubmed: 23209150
Nucleic Acids Res. 2019 May 7;47(8):3811-3827
pubmed: 30799503
Semin Cell Dev Biol. 2017 Mar;63:123-134
pubmed: 27908606
Trends Cell Biol. 2011 Sep;21(9):534-42
pubmed: 21741840
Nutr J. 2016 Jul 25;15(1):71
pubmed: 27456681
Genes (Basel). 2017 Aug 07;8(8):
pubmed: 28783137
Gastroenterology. 2005 Jun;128(7):1919-36
pubmed: 15940627
Cells. 2019 Dec 12;8(12):
pubmed: 31842403
J Biol Chem. 2012 Apr 13;287(16):12975-84
pubmed: 22337872
Invest New Drugs. 2013 Apr;31(2):461-8
pubmed: 23054213
Cancers (Basel). 2020 Mar 29;12(4):
pubmed: 32235397
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Precis Clin Med. 2020 Sep;3(3):187-201
pubmed: 32983586
Sci Rep. 2020 Jul 1;10(1):10725
pubmed: 32612211
Acta Naturae. 2015 Jul-Sep;7(3):27-37
pubmed: 26483957
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340362
Biochem Pharmacol. 2019 Sep;167:33-43
pubmed: 30910692
Mol Oncol. 2019 Apr;13(4):681-700
pubmed: 30714316
Drugs R D. 2020 Jun;20(2):55-73
pubmed: 32215876
Chem Rev. 2015 Mar 25;115(6):2453-81
pubmed: 25575290
Int J Mol Sci. 2020 Apr 16;21(8):
pubmed: 32316192
Front Oncol. 2014 Feb 28;4:42
pubmed: 24616882
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Cancer Cell Int. 2015 Feb 04;15(1):14
pubmed: 25685067
Biochemistry. 2014 Mar 25;53(11):1779-88
pubmed: 24588584
Cell Prolif. 2016 Aug;49(4):421-37
pubmed: 27329285
Cancer Metastasis Rev. 2013 Dec;32(3-4):377-89
pubmed: 23709119
Oncology (Williston Park). 2019 Jul 15;33(7):
pubmed: 31365755
Front Oncol. 2013 Nov 27;3:290
pubmed: 24350055
Semin Cancer Biol. 2015 Dec;35 Suppl:S5-S24
pubmed: 25869442
FEBS J. 2005 Sep;272(18):4576-89
pubmed: 16156780
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Int J Mol Sci. 2020 Aug 28;21(17):
pubmed: 32872305
Transl Oncol. 2017 Apr;10(2):190-196
pubmed: 28182994
Dev Cell. 2007 Jan;12(1):17-30
pubmed: 17199038
Nat Rev Mol Cell Biol. 2018 Mar;19(3):192-206
pubmed: 29018282
Transl Oncol. 2008 Jul;1(2):57-64
pubmed: 18633460
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
J Cancer. 2017 Jun 3;8(9):1586-1597
pubmed: 28775778
BMC Cancer. 2011 Sep 26;11:412
pubmed: 21943092
Nucleic Acids Res. 2019 Sep 5;47(15):7914-7928
pubmed: 31216030
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Adv Exp Med Biol. 2009;656:75-84
pubmed: 19928354
Gastroenterology. 2008 Oct;135(4):1079-99
pubmed: 18773902
Sci Rep. 2019 Jul 16;9(1):10276
pubmed: 31311954
Oncogene. 2012 Dec 6;31(49):5099-107
pubmed: 22286760
Oncologist. 2020 Jan;25(1):33-45
pubmed: 31383813
Genomics Proteomics Bioinformatics. 2016 Jun;14(3):131-139
pubmed: 27240471
Clin Cancer Res. 2000 Jul;6(7):2860-7
pubmed: 10914735
Curr Probl Cancer. 2011 Jan-Feb;35(1):7-50
pubmed: 21300207
Biomolecules. 2020 May 20;10(5):
pubmed: 32443774
Mol Cell. 2010 Jul 9;39(1):8-24
pubmed: 20603072
Ann Oncol. 2020 Sep;31(9):1135-1147
pubmed: 32512040
Cell Rep. 2018 Sep 25;24(13):3488-3502.e5
pubmed: 30257210
Target Oncol. 2018 Aug;13(4):533-539
pubmed: 30073633
Adv Exp Med Biol. 2013;754:3-29
pubmed: 22956494
Biomed Pharmacother. 2019 Feb;110:473-481
pubmed: 30530050
Biomolecules. 2012 Nov 12;2(4):524-48
pubmed: 24970148
Genes Dev. 2017 Jan 15;31(2):101-126
pubmed: 28202539
PLoS One. 2014 Dec 19;9(12):e115558
pubmed: 25526641
J Biomed Biotechnol. 2011;2011:792362
pubmed: 21490705
Clin Cancer Res. 2003 Jul;9(7):2711-8
pubmed: 12855651